Answers are grounded in this paper and cite their sources.
Exploratory analysis characterizes clinicopathological features and molecular profiles in EBV-positive SCNEC-nasopharynx, suggesting new diagnostic and therapeutic approaches.
Background Epstein–Barr virus (EBV)‐positive small cell neuroendocrine carcinoma of the nasopharynx (SCNEC‐nasopharynx) is exceptionally rare and aggressive, with poorly characterized molecular features. Methods Clinicopathological, immunohistochemical (synaptophysin, INSM1, chromogranin A, CK‐pan, EGFR, NUT, INI1), and molecular profiles of 15 EBV‐positive SCNEC‐nasopharynx cases (2012–2025) were analysed. EBV status was confirmed by EBER‐ISH. Exploratory next‐generation sequencing compared nine SCNEC with five EBV‐positive nasopharyngeal non‐keratinizing carcinomas (NKUC). Results Patients (median age 51; male:female = 2:1) presented with advanced‐stage disease and cervical lymphadenopathy. Histology showed solid nests of small cells with high‐grade features. All tumours were diffusely positive for synaptophysin and EBER, showed perinuclear dot‐like CK‐pan staining, and were negative for squamous markers and EGFR. NUT was negative and INI1 retained. Comparative genomics revealed greater mutational burden and unique alterations enriched in cell cycle/DNA damage pathways in SCNEC versus NKUC. After multimodal therapy, median overall survival was 33 months. Conclusion This largest integrated study defines the distinct clinicopathological and molecular profile of EBV‐positive SCNEC‐nasopharynx. The identified diagnostic immunophenotype and potential oncogenic pathways provide a foundation for precise diagnosis and future targeted therapy development.
No takes yet. Share an insight, caveat, or question.
Jian‐ping et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: